Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors

Curr Top Med Chem. 2019;19(23):2114-2127. doi: 10.2174/1568026619666190902145116.

Abstract

The Ras proteins play an important role in cell growth, differentiation, proliferation and survival by regulating diverse signaling pathways. Oncogenic mutant K-Ras is the most frequently mutated class of Ras superfamily that is highly prevalent in many human cancers. Despite intensive efforts to combat various K-Ras-mutant-driven cancers, no effective K-Ras-specific inhibitors have yet been approved for clinical use to date. Since K-Ras proteins must be associated to the plasma membrane for their function, targeting K-Ras plasma membrane localization represents a logical and potentially tractable therapeutic approach. Here, we summarize the recent advances in the development of K-Ras plasma membrane localization inhibitors including natural product-based inhibitors achieved from high throughput screening, fragment-based drug design, virtual screening, and drug repurposing as well as hit-to-lead optimizations.

Keywords: Cancer; Drug discovery; K-Ras; K-Ras mutation; Plasma membrane localization inhibitors; RAS..

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / chemistry
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Cell Membrane / drug effects*
  • Cell Membrane / metabolism*
  • Drug Evaluation, Preclinical*
  • Drug Repositioning
  • Humans
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Oncogene Protein p21(ras) / genetics
  • Oncogene Protein p21(ras) / metabolism*

Substances

  • Antineoplastic Agents, Phytogenic
  • Biological Products
  • Oncogene Protein p21(ras)